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A R T I C L E   I N F O A B S T R A C T 
Brexit raises a number of difficult questions with regard to intellectual property 
rights in a post-Brexit world, particularly for UK based pharma companies.  Whilst 
the position with regard to the current European patent system is unchanged, the 
fate of the unitary patent and the unified patent court remains uncertain. Of more 
immediate concern is the possible future position with respect to supplementary 
patent certificates. Should the UK fail to reach an agreement with the EU with 
respect to marketing authorisations for new pharmaceuticals then there is a real 
possibility that UK based pharma companies may find themselves in a position 
where they are unable to obtain EU-wide SPC protection.  
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INTRODUCTION 
On 23 June 2016 the people of the UK voted (by a slim 
majority) in favour of leaving the European Union.   
Since that time the government has suggested that it 
intends to pursue a so-called “hard” Brexit - a clean 
break from the EU.  The primary intention of this clean 
break is to put the UK in a position wherein it is no 
longer bound by the laws of the EU, and no longer 
falls within the jurisdiction of the Court of Justice of 
the European Union (CJEU) (GovUK 2017a). 
So what could a clean break from the EU mean for UK 
and EU intellectual property rights, particularly for 
the pharmaceutical industry? 
The following takes a brief look at the potential impact 
upon patents and supplementary protection 
certificates following Brexit. To prevent this opinion 
piece from becoming the length of an international 
treaty, the effect of Brexit on other IP rights (designs, 
copyright, trademarks) and issues associated with the 
use of IP rights (such as competition law, exhaustion 
of rights, etc.) will not be discussed in this article. 
PATENTS 
The current system for obtaining patent protection in 
the UK and in the EU will remain the same.  This is 
because the European Patent Office (EPO), which 
examines and grants European patents, is not an EU 
institution and does not fall within the jurisdiction of 
the CJEU. 
In the current European patent system, a European 
patent application is examined centrally by the EPO.  
Once the EPO is satisfied that the requirements for 
grant have been met, it grants a European patent.  The 
European patent is then validated in as many of the 
contracting states, extension states and validation 
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states (EPO 2017a) as desired, at which point it 
becomes a bundle of individual national patents (one 
granted national patent for each validated state).  
In an attempt to simplify this process, a new system 
has been developed - the Unitary Patent (UP) and the 
Unified Patent Court (UPC).  The aim of this system is 
to (eventually) make it possible to obtain patent 
protection in up to 26 EU Member States through a 
single pan-European patent (rather than a plurality of 
national patents) and litigate centrally (rather than 
litigate each national patent in each separate 
jurisdiction) (EPO 2017b). 
The UP/UPC therefore may be an attractive option to 
the pharma industry, as it would allow for reduced 
litigation costs and reduced patent renewal fees.  Of 
course, the down side to the holder of a UP vis-à-vis 
the current European patent system would be the 
risks associated with central revocation of a UP (i.e. 
significant loss of EU patent coverage in a single 
action) coupled with the fact that the UPC would be a 
new and therefore untested court system. 
The UP and the UPC will be governed by EU law 
(under “the Agreement on a Unified Patent Court” 
(UPCA) (UPC 2017a) and the CJEU will have 
jurisdictional primacy.  For the UPCA to come into 
force, the UPCA must be signed and ratified by 13 EU 
Member States, including France, Germany and the 
UK (UPC 2017b) 
Prior to the Brexit vote, ratification by the UK would 
have been little more than a formality. However, 
following the Brexit vote it seemed that the UP and 
UPC could quite possibly be dead in the water. 
It was therefore rather surprising that in November 
2016 the UK government announced its intention to 
ratify the UPCA.  This appeared to be at odds with the 
government’s current political position; on the one 
hand the government wanted to bring the UPCA (i.e. 
EU law) into force in the UK post-Brexit, and on the 
other hand wanted to distance a post-Brexit UK from 
EU laws. This conflict is therefore likely to cause some 
significant problems in the future. 
However, at present the situation is that the UPCA 
will be ratified and brought into force in the UK in the 
not too distant future – the entry into force date is 
estimated to be sometime in early 2018 (however, this 
date could be further delayed due to a recent legal 
challenge to the UPC in Germany) (IPKat 2017). But 
what happens when the UK leaves the EU in 2019? 
There will be transitional period in place for an 
unspecified period of time (GovUK 2017b), but no 
specifics of the transitional arrangements have yet 
been provided. Without the specifics of those 
arrangements it is not possible to say what may or 
may not happen to the UP/UPC system immediately 
after the UK leaves the EU.  It is also too early to say 
whether the UK would continue to participate in the 
UP/UPC after the conclusion of Brexit.   
This also begs the question of what might happen to 
the proposed London based central division of the 
UPC, which will hear cases relating to chemistry, 
including pharmaceuticals and the life sciences.  In a 
recent press conference (EC 2017) Michael Barnier, 
when questioned over the possible relocation of the 
London based central division of the UPC, stated that 
“we are looking into it”.  The fate of the London based 
central division of the UPC would therefore appear 
uncertain. 
SUPPLEMENTARY PROTECTION 
CERTIFICATES (SPCS)  
SPCs are an important additional form of protection 
for the pharmaceutical industry. They can extend the 
normal 20 year term of patents relating to medicinal 
or plant protection products by up to 5 years (5½ years 
for paediatric medicines).  That patent term extension 
is to compensate for the time taken to obtain 
authorisation to place the relevant product on the 
market. 
SPCs are a national IP right, not a pan-EU IP right; 
each national SPC must be registered in each 
individual EU member state.  In order to obtain an 
SPC in an EU member state, it is necessary to hold 
both a valid national patent in that EU member state 
that protects the active ingredient and a valid 
marketing authorisation (MA) to place the active 
ingredient on the market of that EU member state as a 
pharmaceutical or plant protection product (GovUK 
2017c). In the UK, the bodies that may grant MAs are 
primarily the Medicines and Healthcare Products 
Regulatory Authority (MHRA) and the EMA, a 
decentralised agency of the EU which evaluates 
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medicines throughout their life cycle and issues MAs 
for approved medicines. 
The legal basis for SPCs in the UK is derived from EU 
regulations (EC 1996, 2009) therefore upon leaving the 
EU those laws will cease to apply to the UK.   
However, the “Great Repeal Bill” is intended to 
convert directly-applicable EU laws (i.e. EU 
regulations) into UK law (GovUK 2017a). As such, it 
would seem that there may not be a hiatus in the 
protection provided by current SPCs or in obtaining 
new SPCs within the UK, but again this is a rather 
uncertain area that will require clarifying in due 
course. 
Perhaps more worryingly for pharmaceutical 
companies based solely in the UK (e.g. SMEs or 
overseas pharma companies with their EU base 
located in the UK) is the position in which they might 
find themselves in a post-Brexit UK when looking to 
obtain EU-wide SPC protection. 
Pre-Brexit, the most efficient and hence most 
commonly used procedure for obtaining an SPC in 
several EU member states was to obtain a MA from 
the EMA, and use that MA to register an SPC in each 
of the EU member states in which the pharmaceutical 
company has a valid national patent.  This was a 
reasonably streamlined process. 
However, following Brexit, the UK’s membership of 
the EMA is at risk.  There is no provision in the law 
regulating the EMA (EC 2004) for participation of the 
EMA with non-EU states.  As such, any future UK 
membership of the EMA (or perhaps even an 
equivalent reciprocal agreement between the UK and 
the EMA) will be dependent on Brexit negotiations. So 
what effect could this have on current and future MAs 
issued by the EMA? 
A recent EU Commission and EMA Notice (EMA 
2017a) would appear to be a warning shot to UK based 
companies who currently hold an MA issued by the 
EMA.  That notice reiterates certain residency and 
activity requirements for MA holders (EMA 2017b): 
• EU law requires that marketing authorisation 
holders are established in the EU or EEA; and 
• Some activities must be performed in the EU or 
EEA, related for example to pharmacovigilance, 
batch release, etc. 
Furthermore, that notice expressly states that 
“marketing authorisation holders may be required to 
adapt processes and to consider changes to the terms 
of the marketing authorisation in order to ensure its 
continuous validity and exploitation, once the United 
Kingdom has left the Union”. A subsequent notice 
from the Commission and EMA (EMA 2017c) states 
that MA holders established in the UK “will normally 
need to transfer [their] marketing authorisation to a 
holder established in the Union (EEA)”. That 
subsequent notice also sets out further activity 
requirements that may have to be transferred to the 
EEA. 
The reference to “continuous validity and 
exploitation” of MAs may be an implicit warning to 
companies based in the UK that, unless the above 
requirements are met, the legal validity of their EMA 
issued MA may be called into question.  If this is 
correct, then that would also seem to imply that the 
legal validity of any granted SPCs based thereupon 
might be called into question (considering that the 
SPC may no longer be based on a valid MA). 
Those notices from the Commission and EMA would 
therefore seem to be suggesting that UK based 
pharma companies may have to consider either 
collaborating/merging with EU based pharma 
companies, or relocating at least some of their 
commercial residence and R&D activities to an EEA 
member state if they wish to maintain their current 
MAs issued by the EMA and obtain further MAs from 
the EMA.  That, of course, would be detrimental to 
pharmaceutical R&D in the UK, thereby reiterating 
the need for the UK to promptly strike a deal with the 
EU on this front. 
Following this theme, in the EU/EEA it is currently a 
compulsory requirement for pharma companies to 
obtain an MA from the EMA for the following (EMA 
2007): 
• new active ingredients indicated for HIV, cancer, 
diabetes, neuro-degenerative diseases, 
autoimmune dysfunctions and viral diseases; 
• medicines derived from biotechnology processes, 
such as genetic engineering; 
• advanced-therapy medicines, such as gene-
therapy, somatic cell-therapy or tissue-engineered 
medicines; 
• orphan medicines (medicines for rare diseases); 
and 
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• veterinary medicines for use as growth or yield 
enhancers. 
This raises the question of how a UK based company 
developing any of the above medicines would be able 
to obtain marketing authorisation for its newly 
developed medicine in the EU/EEA post-Brexit (bar 
altering its commercial residency and activities).  If it 
is not possible for such companies to obtain an MA in 
the EU/EEA then (notwithstanding the impact which 
that alone may have on such companies) the 
implication may be that SPC protection may no longer 
be available to those companies unless they “set up 
shop” in the EU/EEA.  
As a final passing comment regarding SPCs, the EU 
Commission is currently looking into the possibility 
of having a single pan-EU SPC based on a UP.  This is 
still in the embryonic stages of its life cycle, but 
hopefully the Commission will publish a report on its 
findings in the not too distant future. 
CONCLUSIONS 
The current European patent system will continue to 
function as it has done for the past 40 years, and 
patents will continue to be examined and granted in 
the usual manner with no interruption to service.   
With regard to the immediate fate of the UP/UPC, it 
is really too soon to tell what is going to happen post-
Brexit.  The “best-case scenario” would be a fully 
functional UP/UPC system that is up and running by 
spring 2018.  The “worst-case scenario” would be the 
UP/UPC system being scrapped in its entirety.  The 
likely outcome could quite possibly fall somewhere in 
between the two extremes.   
The situation with regard to SPCs looks to be 
somewhat more challenging and complex, 
particularly with regard to the implications of the UK 
no longer being a member of the EMA. Again, it is 
really too soon to tell what is going to happen post-
Brexit.  However, one may speculate that if the 
situation regarding MAs is not sorted out quickly then 
we could quite possibly see a number of existing UK 
pharma companies move their base of operations to 
the EU, and in the future pharma companies looking 
to set up in Europe may favour an EU member state 
over the UK.  Both of those hypothetical situations 
would be detrimental to pharmaceutical R&D in the 
UK. 
A prudent and rather straightforward solution to all 
of the above issues may be for the UK to agree to 
remain bound by EU law for intellectual property 
matters.  The current political climate, however, 
would seem to preclude such a scenario. 
So, in conclusion, it would seem that a “clean break” 
from the EU may (somewhat unsurprisingly) cause 
more legal issues than it may solve for pharmaceutical 
related IP. Given that Brexit has produced a legal 
quagmire in the UK, the Authors would be rather 
surprised if these specific issues were given priority 
during the Brexit negotiations or debated in 
parliament any time soon.  We could be waiting a 
while for much needed answers, but hopefully not too 
long. 
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